Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Northside Hospital

Neither a doctor nor a teaching hospital

Research payments

$4,354,701

250 payments

Through program year 2025, Northside Hospital is reported as receiving $4,354,701 in research payments, across 250 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $19,652 7
2024 Research $59,970 14
2023 Research $32,502 6
2022 Research $26,217 12
2021 Research $1,706,776 11
2020 Research $1,639,325 115
2019 Research $870,258 85

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $1,176,795 4 payments
  2. Pharmacyclics LLC, An AbbVie Company $1,143,882 5 payments
  3. Merck Sharp & Dohme Corporation $687,516 48 payments
  4. Seattle Genetics, Inc. $313,158 56 payments
  5. Celgene Corporation $305,090 3 payments
  6. Astellas Pharma Global Development $141,566 7 payments
  7. GlaxoSmithKline, LLC. $112,458 29 payments
  8. TESARO, Inc. $86,420 5 payments
  9. Boston Scientific Corporation $73,871 15 payments
  10. Medtronic USA, Inc. $64,948 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase I Open Label Study to Evaluate the Safety Pharmacokinetic Pharmacodynamic and Clinical Activity of Pf06863135 A Bcell Maturation Antigen Bcma Cd3 Bispecific Antibody As A Single Agent and in Combination With Immunomodulatory Agents in Patients With Relapsedrefractory Advanced Multiple Myeloma MM $1,166,295 3 payments
  2. Phase II Trial Evaluating the Safety and Efficacy of Combined CD20- and BTK-Targeted B Cell Depleting Therapy with Rituximab and Ibrutinib in the Primary Treatment of Extensive Chronic Graft-Versus-Host Disease $1,143,882 5 payments
  3. Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 $420,569 21 payments
  4. A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM) (JCAR017-BCM-003) $273,393 1 payment
  5. Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 $179,938 9 payments
  6. Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer $148,831 11 payments
  7. Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib $120,552 24 payments
  8. A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3ITD AML $96,681 4 payments
  9. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Hrd-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy $86,420 5 payments
  10. A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the E $82,803 19 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record